CLINICAL TRIALS PROFILE FOR CARNITOR

All Clinical Trials for CARNITOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00227266 ↗	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Completed	Abbott	Phase 2	2005-09-01	This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
NCT00227266 ↗	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Completed	Families of Spinal Muscular Atrophy	Phase 2	2005-09-01	This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
NCT00227266 ↗	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Completed	Leadiant Biosciences, Inc.	Phase 2	2005-09-01	This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
NCT00227266 ↗	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Completed	Sigma Tau Pharmaceuticals, Inc.	Phase 2	2005-09-01	This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
NCT00227266 ↗	Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy	Completed	University of Utah	Phase 2	2005-09-01	This is a multi-center trial to assess safety and efficacy of a combined regimen of oral valproic acid (VPA) and carnitine in patients with Spinal Muscular Atrophy (SMA) 2 to 17 years of age. Cohort 1 is a double-blind placebo-controlled randomized intention to treat protocol for SMA "sitters" 2 - 8 years of age. Cohort 2 is an open label protocol for SMA "standers and walkers" 3 - 17 years of age to explore responsiveness of efficacy outcomes. Outcome measures will include blood chemistries, functional testing, pulmonary function testing, electrophysiological evaluations, PedsQL quality of life assessment, quantitative assessments of survival motor neuron (SMN) mRNA from blood samples, growth and vital sign parameters. Six centers will enroll a total of 90 patients.
NCT00481013 ↗	Valproic Acid in Ambulant Adults With Spinal Muscular Atrophy	Completed	Abbott	Phase 2	2007-07-01	The primary objective of this proposal is to determine whether oral VPA is effective in treating SMA in adult patients.

Clinical Trial Conditions for CARNITOR

Condition Name

Condition Name for CARNITOR
Intervention	Trials
Spinal Muscular Atrophy	2
Carnitine Deficiency	2
Mixed Phenotype Acute Leukemia	1
Neurodevelopmental Disorder	1

Condition MeSH

Condition MeSH for CARNITOR
Intervention	Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	2
Leukemia, Lymphoid	2
Leukemia	2
Muscular Atrophy, Spinal	2

Clinical Trial Locations for CARNITOR

Trials by Country

Trials by Country for CARNITOR
Location	Trials
United States	9
Canada	2
Netherlands	1

Trials by US State

Trials by US State for CARNITOR
Location	Trials
Ohio	2
Georgia	1
Texas	1
New York	1
Wisconsin	1

Clinical Trial Progress for CARNITOR

Clinical Trial Phase

Clinical Trial Phase for CARNITOR
Clinical Trial Phase	Trials
PHASE2	1
Phase 4	1
Phase 3	1

Clinical Trial Status

Clinical Trial Status for CARNITOR
Clinical Trial Phase	Trials
Completed	2
Active, not recruiting	1
Recruiting	1

Clinical Trial Sponsors for CARNITOR

Sponsor Name

Sponsor Name for CARNITOR
Sponsor	Trials
University of Utah	2
Abbott	2
Families of Spinal Muscular Atrophy	2

Sponsor Type

Sponsor Type for CARNITOR
Sponsor	Trials
Other	12
Industry	4
NIH	1

Carnitor (L-carnitine) Clinical Trials Update, Market Analysis, and Exclusivity/Generic Risk Projection

Last updated: July 27, 2026

Carnitor (L-carnitine; chemical also known as levocarnitine) is a widely used metabolic therapy across primary and secondary carnitine deficiency. This product category is characterized by long-term use, multiple approved L-carnitine salt/drug forms in different jurisdictions, and a competitive environment where “generic” exposure often comes via additional marketing authorizations rather than long, patent-driven exclusivity blocks. No current, attributable clinical-trials feed or actionable U.S. FDA Orange Book patent listing for “Carnitor” specifically is provided in the available inputs, so a litigation-grade exclusivity calendar and a precise FDA-patent landscape cannot be produced here.

What is Carnitor (L-carnitine) and what clinical indications does it target?

Featured snippet answer: Carnitor is an L-carnitine replacement therapy used to treat primary (genetic) carnitine deficiency and as adjunctive treatment in certain secondary carnitine deficiencies. It is also used in metabolic support settings where clinicians target carnitine depletion states.

What conditions are most commonly linked to L-carnitine therapy?

L-carnitine indications typically include:

• Primary carnitine deficiency (PCD), including ongoing lifelong treatment
• Secondary carnitine deficiency in settings such as:
  • dialysis-associated carnitine loss (common in chronic hemodialysis)
  • inborn errors of metabolism where organic acidemias can lead to secondary carnitine depletion
  • valproate-associated carnitine depletion in clinical practice contexts (where supported by local labeling and clinical guidelines)

Which dosage forms matter for market and substitution risk?

Market substitution and payer access depend on whether products are:

• Oral solutions (common for pediatric and chronic regimens)
• Tablets (adult adherence)
• Injectable formulations (hospital use)
• Concentration-specific variants that may drive formulary positioning

What clinical trials are currently in progress for Carnitor or L-carnitine, and what endpoints do they use?

Featured snippet answer: A complete “currently in progress” trials update requires an authoritative clinical trials register feed (e.g., ClinicalTrials.gov with study IDs tied to the branded trade name and/or the exact sponsor/product). That feed is not included in the provided inputs, so a precise, attributable update cannot be produced.

Common trial designs and endpoints in L-carnitine programs

When new L-carnitine studies run, they typically measure:

• Pharmacokinetics and tissue or plasma carnitine levels (free carnitine and acylcarnitine species)
• Clinical metabolic endpoints tied to specific disorders (growth, hospitalization rates, metabolic stability)
• Safety in pediatric populations and in chronic dosing contexts (gastrointestinal effects, trimethylamine-related odor reported in some settings)

What would change the competitive landscape in a trials readout?

Market-shifting results would usually come from:

• New approved indications that expand patient volume
• New formulations that improve adherence or reduce monitoring burden
• Evidence supporting use in specific drug-induced deficiency states that expand prescribing beyond rare disease settings

How does Carnitor’s market position look today: sizing, pricing pressure, and payer dynamics?

Featured snippet answer: Carnitor’s market is driven by chronic replacement therapy demand in primary carnitine deficiency and secondary deficiency states, with pricing pressure influenced by the breadth of competing L-carnitine products and local availability.

Demand drivers

• Lifelong treatment for primary carnitine deficiency
• Ongoing dialysis and metabolic-disorder care in which clinicians use L-carnitine to manage deficiency
• Pediatric use where dose flexibility across oral solutions can be important

Key market constraints

• Fragmentation across salts, concentrations, and dosage forms
• Formulary substitution toward lower-cost L-carnitine products where interchangeability is accepted
• Regulatory differences across countries affecting local exclusivity and generic entry timelines

Competitive set logic

For a product like Carnitor, competition typically forms along two axes:

• Same active ingredient, different marketing authorization holders and bottle-concentration and delivery differences
• Competing metabolic or ammonia/organic acid management approaches when used in specific disorders, though those are often not direct substitutes

What market projection is reasonable for Carnitor over the next 3–7 years?

Featured snippet answer: Without a source-backed baseline revenue, share, or country-level launch/availability timeline, a quantified projection cannot be stated accurately. A directionally valid view is that growth is tied to expanding diagnosed patient pools and stable chronic treatment demand, while margin growth is capped by substitution and normalized pricing.

Projection components that typically determine outcome

• Patient pool growth (diagnosis rates, newborn screening adoption in some regions)
• Utilization expansion into secondary deficiency settings
• Pricing and tender dynamics (especially where tender-based procurement drives lowest-cost selection)
• Regulatory approvals for additional L-carnitine products affecting competitive intensity

What would accelerate growth?

• New guideline endorsements in specific deficiency contexts
• Expanded label indications in major markets
• A formulation change that improves adherence and reduces administration friction

What would depress growth?

• Intensified substitution through additional marketing authorizations
• Payer restrictions in low-evidence secondary use settings
• Manufacturing supply disruptions that drive switching and long-term contracting changes

When does Carnitor lose exclusivity in the U.S., and what patents protect L-carnitine formulations?

Featured snippet answer: A precise exclusivity-loss date and the number of protecting patents for “Carnitor” cannot be stated because the underlying patent list for the specific U.S. marketed product is not provided.

What the patent estate typically covers for legacy metabolic replacements

For products like L-carnitine, if patents exist, they more often cluster around:

• Specific formulations (salt form, concentration, excipients, stability)
• Manufacturing methods (process-specific)
• Methods of use (rare and often narrower due to replacement nature)

What you need for a litigation-grade timeline

A litigation-grade calendar requires:

• Orange Book listing tied to the exact brand (or application reference)
• Patent numbers, expiration dates, and patent type (composition, method, formulation)
• Whether pediatric exclusivity, marketing exclusivity, or orphan exclusivity applies (if any) to that exact NDA/ANDA/BLA

Those inputs are not available in the provided material, so no exclusivity calendar is produced.

What is the Orange Book status of Carnitor, and which generic entry risks exist?

Featured snippet answer: Orange Book status cannot be determined from the provided inputs.

Paragraph IV risk assessment logic (what would matter)

If an Orange Book listing exists for Carnitor:

• Identify which patents are method-of-use vs. formulation vs. composition
• Determine whether any are eligible for Paragraph IV certification
• Map to likely ANDA entrants by formulation capability and dosage form

Without the Orange Book listing details, a risk assessment cannot be made.

Is Carnitor being challenged with ANDAs or litigated in the U.S.?

Featured snippet answer: No litigation posture can be provided because no case docket details, settlement announcements, or Paragraph IV notices are included in the inputs.

What to look for in litigation affecting market entry

For a replacement therapy, litigation tends to be driven by:

• Formulation-specific patents
• Product-specific manufacturing process patents
• Narrow method-of-use claims tied to specific disorder subtypes

How does Carnitor compare with other L-carnitine products on the market?

Featured snippet answer: The meaningful comparison is typically by:

• dosage form (solution vs tablets vs injection)
• concentration and excipient profile (impact on pediatric dosing and tolerance)
• supply continuity and contracting terms (payer and hospital formularies)

A brand vs. generic side-by-side list requires product-level labeling and regulatory data not included in the inputs.

Key Takeaways

• Carnitor is an L-carnitine replacement therapy used for primary carnitine deficiency and selected secondary deficiency states.
• A complete clinical trials update cannot be produced without a trial registry feed tied to Carnitor or its specific L-carnitine product.
• A quantified market projection cannot be stated without baseline revenue, share, and regional approval and availability data.
• Exclusivity, Orange Book status, and generic entry/litigation risk for “Carnitor” cannot be computed because the underlying patent and regulatory listings are not provided.

FAQs

1. What are the most common clinical endpoints measured in L-carnitine trials for deficiency states?
2. How do dosing form and concentration differences affect substitution and formulary access for L-carnitine brands?
3. What factors drive diagnosis-rate growth for primary carnitine deficiency in major markets?
4. How do payer tender models typically influence pricing for chronic metabolic replacement therapies?
5. What patent categories most often determine generic entry risk for legacy metabolic products like L-carnitine?

References

(No sources were cited because no drug-specific trials, Orange Book listings, patent numbers, litigation dockets, or FDA regulatory milestones were provided in the input.)